Adult lifetime cannabis use by country is the lifetime prevalence of cannabis use among all adults in surveys among the general population. [1] [2] Lifetime prevalence means any use of cannabis during a person's life. [3]
Location | Geographical area | Year | Age range | Males | Females | Total | Ref. |
---|---|---|---|---|---|---|---|
Australia * | National | 2007 | 14+ | 33.5 | [4] | ||
Austria * | National | 2020 | 15–64 | 24.8 | 20.6 | 22.7 | [1] |
Belgium * | National | 2018 | 15–64 | 28.1 | 17.3 | 22.6 | [1] |
Brazil * | National | 2018 | 15–64 | 14.0 | [5] | ||
Bulgaria * | National | 2020 | 15–64 | 9.5 | 7.8 | 8.7 | [1] |
Canada * | National | 2005 | 15+ | 44.5 | [6] | ||
Chile * | National | 2014 | 12–64 | 31.5 | [7] | ||
China * | Beijing and Shanghai metropolitan areas. | 2002–3 | 18+ | 0.3 | [2] | ||
Colombia * | All urban areas of the country (approximately 73% of the total national population). | 2003 | 18–65 | 10.8 | [2] | ||
Croatia * | National | 2019 | 15–64 | 28.8 | 16.9 | 22.9 | [1] |
Cyprus * | National | 2019 | 15–64 | 21.5 | 7.1 | 14.1 | [1] |
Czech Republic * | National | 2021 | 15–64 | 31.1 | 21.1 | 25.9 | [1] |
Denmark * | National | 2021 | 15–64 | 44 | 32 | 37.9 | [1] |
Estonia * | National | 2018 | 15–64 | 30.8 | 20.3 | 24.5 | [1] |
Finland * | National | 2018 | 15–64 | 29.8 | 21.3 | 25.6 | [1] |
France * | National | 2021 | 15–64 | 54.9 | 39.9 | 47.3 | [1] |
Germany * | National | 2021 | 15–64 | 38.9 | 30.2 | 34.7 | [1] |
Greece * | National | 2015 | 15–64 | 15.8 | 6.3 | 11 | [1] |
Hungary * | National | 2019 | 15–64 | 8.4 | 4 | 6.1 | [1] |
Ireland * | National | 2019 | 15–64 | 29.5 | 19.3 | 24.4 | [1] |
Israel * | National | 2002–4 | 21+ | 11.5 | [2] | ||
Italy * | National | 2017 | 15–64 | 39.1 | 26.4 | 32.7 | [1] |
Japan * | Four metropolitan areas (Fukiage, Kushikino, Nagasaki, Okayama). | 2002–3 | 20+ | 1.5 | [2] | ||
Latvia * | National | 2020 | 15–64 | 22 | 8.2 | 15 | [1] |
Lebanon * | National | 2002–3 | 18+ | 4.6 | [2] | ||
Lithuania * | National | 2021 | 15–64 | 20.7 | 6.8 | 13.7 | [1] |
Luxembourg * | National | 2019 | 15–64 | 27.8 | 19.6 | 23.3 | [1] |
Malta * | National | 2013 | 15–64 | 6.7 | 2 | 4.3 | [1] |
Mexico * | All urban areas of the country (approximately 75% of the total national population). | 2001–2 | 18–65 | 7.8 | [2] | ||
Nepal * | All urban areas of the country (approximately 80% of the total national population). | 2001–2 | 18–65 | 7.8 | [2] | ||
Netherlands * | National | 2021 | 15–64 | 35.7 | 23.9 | 29.8 | [1] |
New Zealand * | National | 2004–5 | 16+ | 41.9 | [2] | ||
Nigeria * | 21 of the 36 states in the country, representing 57% of the national population. | 2002–3 | 18+ | 2.7 | [2] | ||
Norway * | National | 2024 | 16–64 | 35.0 | 24.0 | 30.0 | [8] |
Peru * | Seven cities (Lima, Trujillo, Tacna, Arequipa, Ayacucho, Tarapoto and Iquitos) | 2003 | 12–64 | 10.3 | [9] | ||
Poland * | National | 2018 | 15–64 | 16.4 | 7.7 | 12.1 | [1] |
Portugal * | National | 2016 | 15–64 | 15.6 | 6.6 | 11 | [1] |
Romania * | National | 2019 | 15–64 | 8 | 4.3 | 6.1 | [1] |
Slovakia * | National | 2019 | 15–64 | 23.4 | 10.6 | 17 | [1] |
Slovenia * | National | 2018 | 15–64 | 24.7 | 16.5 | 20.7 | [1] |
South Africa * | National | 2003–4 | 18+ | 8.4 | [2] | ||
Spain * | National | 2022 | 15–64 | 48.8 | 32.9 | 40.9 | [1] |
Sweden * | National | 2021 | 15–64 | 21.9 | 13.1 | 17.6 | [1] |
Turkey * | National | 2017 | 15–64 | 5.4 | 0.2 | 2.7 | [1] |
Ukraine * | National | 2002 | 18+ | 6.4 | [2] | ||
England and Wales * (UK) | National | 2021-22 | 16–59 | 31.2 | [10] | ||
Northern Ireland * (UK) | National | 2010–11 | 15–64 | 24.0 | [11] | ||
Scotland * (UK) | National | 2010–11 | 16–64 | 26.7 | [11] | ||
United Kingdom * | United Kingdom overall | 2006 | 16–59 | 30.2 | [11] | ||
United States * | National | 2023 | 18+ | 49 | [12] |
European Monitoring Centre for Drugs and Drug Addiction has an interactive cannabis use map of Europe. One can select by recall period: last month, last year, or lifetime. Also by age: young adults (15–34), or adults (15–64). Hover over a country for the data. [13]
A non-interactive map is below.
Recreational drug use is the use of one or more psychoactive drugs to induce an altered state of consciousness, either for pleasure or for some other casual purpose or pastime. When a psychoactive drug enters the user's body, it induces an intoxicating effect. Recreational drugs are commonly divided into three categories: depressants, stimulants, and hallucinogens.
The short-termeffects of cannabis are caused by many chemical compounds in the cannabis plant, including 113 different cannabinoids, such as tetrahydrocannabinol (THC), and 120 terpenes, which allow its drug to have various psychological and physiological effects on the human body. Different plants of the genus Cannabis contain different and often unpredictable concentrations of THC and other cannabinoids and hundreds of other molecules that have a pharmacological effect, so the final net effect cannot reliably be foreseen. Acute effects while under the influence can sometimes include euphoria or anxiety. Although some assert that cannabidiol (CBD), another cannabinoid found in cannabis in varying amounts, may alleviate the adverse effects of THC that some users experience, little is known about CBD's effects on humans. Cannabinoid receptor antagonists have previously been tested as antidotes for cannabis intoxication with success, reducing or eliminating the physiological and psychological effects of intoxication. Some of these products are currently in development as cannabis antidotes.
The legality of cannabis for medical and recreational use varies by country, in terms of its possession, distribution, and cultivation, and how it can be consumed and what medical conditions it can be used for. These policies in most countries are regulated by three United Nations treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Cannabis was reclassified in 2020 to a Schedule I-only drug under the Single Convention treaty, with the schedules from strictest to least being IV, I, II, and III. As a Schedule I drug under the treaty, countries can allow the medical use of cannabis but it is considered to be an addictive drug with a serious risk of abuse.
The gateway drug effect is a comprehensive catchphrase for the often observed effect that the use of a psychoactive substance is coupled to an increased probability of the use of further substances. Possible reasons for the connection include environmental influence, impulsive people seeking both soft and hard drugs, alterations in the brain due to earlier substance exposure, as well as similar attitudes of people who use different substances, and therefore experience a "common liability to addiction". In 2020, the National Institute on Drug Abuse released a research report which supported allegations that marijuana is a "gateway" to more dangerous substance use; one of the peer-reviewed papers cited in the report claims that while "some studies have found that use of legal drugs or cannabis are not a requirement for the progression to other illicit drugs [...] most studies have supported the "gateway sequence"." However, a 2018 literature review conducted by the National Institute of Justice, which analyzed 23 peer-reviewed research studies, concluded "that existing statistical research and analysis relevant to the "gateway" hypothesis has produced mixed results", and that "no causal link between cannabis use and the use of other illicit drugs can be claimed at this time."
Cannabis, commonly known as marijuana, weed, and pot, among other names, is a non-chemically uniform drug from the cannabis plant. Native to Central or South Asia, the cannabis plant has been used as a drug for both recreational and entheogenic purposes and in various traditional medicines for centuries. Tetrahydrocannabinol (THC) is the main psychoactive component of cannabis, which is one of the 483 known compounds in the plant, including at least 65 other cannabinoids, such as cannabidiol (CBD). Cannabis can be used by smoking, vaporizing, within food, or as an extract.
The National Institute on Drug Abuse (NIDA) is a United States federal government research institute whose mission is to "advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health."
A drug policy is the policy regarding the control and regulation of psychoactive substances, particularly those that are addictive or cause physical and mental dependence. While drug policies are generally implemented by governments, entities at all levels may have specific policies related to drugs.
Drug liberalization is a drug policy process of decriminalizing, legalizing, or repealing laws that prohibit the production, possession, sale, or use of prohibited drugs. Variations of drug liberalization include drug legalization, drug relegalization, and drug decriminalization. Proponents of drug liberalization may favor a regulatory regime for the production, marketing, and distribution of some or all currently illegal drugs in a manner analogous to that for alcohol, caffeine and tobacco.
The use, sale, and possession of cannabis containing over 0.3% THC by dry weight in the United States, despite laws in many states permitting it under various circumstances, is illegal under federal law. As a Schedule I drug under the federal Controlled Substances Act (CSA) of 1970, cannabis containing over 0.3% THC by dry weight is considered to have "no accepted medical use" and a high potential for abuse and physical or psychological dependence. Cannabis use is illegal for any reason, with the exception of FDA-approved research programs. However, individual states have enacted legislation permitting exemptions for various uses, including medical, industrial, and recreational use.
Cannabis is a plant used in Australia for recreational, medicinal and industrial purposes. In 2022–23, 41% of Australians over the age of fourteen years had used cannabis in their lifetime and 11.5% had used cannabis in the last 12 months.
The drug policy of Portugal, informally called the "drug strategy", was put in place in 2000, and came into effect in July 2001. Created by the Decree-Law n. 130 -A/2001 and under the jurisdiction of the Commissions for the Dissuasion of Drug Addiction, its purpose was to reduce the number of new HIV/AIDS cases in the country, as it was estimated around half of new cases came from injection drug use. This new approach focused on public health as opposed to public-order priorities by decriminalizing public and private use and possession of all drugs. Under this new policy when the police encounter individuals using or in possession of drugs, the substance is confiscated and the individual is referred to a Dissuasion Commission.
Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment.
Minors and the legality of cannabis is one of the issues around the legalisation of cannabis, with most jurisdictions placing strict age limits in a similar way as is done with the drinking age for alcohol.
The use of cannabis as a recreational drug has been outlawed in many countries for several decades. As a result of long-fought legalization efforts, several countries such as Uruguay and Canada, as well as several states in the US, have legalized the production, sale, possession, and recreational and/or medical usage of cannabis. The broad legalization of cannabis in this fashion can have numerous effects on the economy and society in which it is legalized.
Cannabis in Denmark is illegal for recreational use, but medical use is allowed through a four-year pilot program initiated in January 2018.
Cannabis in Latvia is illegal for recreational and medical purposes, but production of industrial hemp is permitted.
Cannabis is illegal in Turkey for recreational use, but allowed for limited medical and scientific purposes. The Turkish term for cannabis is kenevir.
{{cite web}}
: CS1 maint: unfit URL (link)The percentage of U.S. adults who say they have tried marijuana has ticked up to 49%
This data explorer enables you to view our data on the prevalence of cannabis use by recall period and age range. You can access data by country by clicking on the map or selecting a country from the dropdown menu.